Reddy's Laboratories in India and multiple clinical trials now underway. We've made important strides in the development of our technology, including the recent licensing and distribution agreement with Dr.
.jpg "bardy diagnostics press release")
#Bardy diagnostics press release free#
Most recently, he served as Head of Digital Health, Diagnostics, and Monitoring at BIOTRONIK, a global leader in the treatment of cardiac and vascular disease.Īmos Ziv, founder and CSO, of CardiaCare adds, "CardiaCare is committed to disrupting the atrial fibrillation treatment paradigm, enabling effective, non-invasive, side-effect free therapy for AFib with our first of its kind home-care wearable technology. He played a significant role in building the teams, cultures, and infrastructures for what have become three of the top four market share players in cardiac digital health and remote patient monitoring (iRhythm Biotelemetry, acquired by Philips Bardy Diagnostics, acquired by HillRom). Then, over the past 12 years, he has led commercial sales and marketing efforts and has launched disruptive wearable technologies in cardiac digital health and remote patient monitoring. Nelson spent just under 10 years in sales and commercial operations leadership roles at Boston Scientific (formerly Guidant) in the Cardiac Rhythm Management division. Ken's prior experience and success scaling cardiac device companies will be invaluable to us as we create global awareness of CardiaCare's disruptive innovation and build out the infrastructure towards successful commercialization of our technology."
Ken joins CardiaCare as the company ramps up multiple clinical trials of our revolutionary wearable for atrial fibrillation treatment. "Ken brings a wealth of market development, commercialization and sales experience in the cardiac monitoring and cardiac rhythm management space. "We are privileged and excited to welcome Ken Nelson to CardiaCare as Chairman of the Board of Directors," said Ofer Halbreich, CEO of CardiaCare. Nelson is a 20-year digital health, medical device, and remote patient monitoring executive with a stellar track record of building successful sales, marketing and commercialization teams at Fortune 500 companies as well as startups. REHOVOT, Israel, /PRNewswire/ - CardiaCare, a clinical stage digital therapeutic company developing the world's first non-invasive, neuromodulation wearable for atrial fibrillation treatment, announced today that Ken Nelson has been appointed Chairman of the Board. Digital health and medtech leader brings 20 years of cardiac innovation and commercialization experience to startup developing AI powered neuromodulation wearable for non-invasive atrial fibrillation treatment
0 kommentar(er)
